Le Lézard
Classified in: Health, Science and technology
Subjects: Product/Service, Personnel

Cardior Welcomes Dr. Orly Vardeny as Permanent Guest to the Board


Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced that Orly Vardeny, PharmD, MS, joins its Board of Directors as a permanent guest. Dr. Vardeny is an Associate professor of Medicine at the University of Minnesota Medical School, with a research focus on novel therapies for the treatment of heart failure and a track record of conducting clinical trials for cardiovascular diseases. Dr. Vardeny's insights will be invaluable as Cardior advances its pipeline of RNA-based therapeutics headed by lead candidate CDR132L, which is currently under evaluation in the HF-REVERT Phase 2 clinical trial in heart failure patients post-myocardial infarction.

"As we further develop our broad pipeline of potentially revolutionary RNA therapeutics for heart diseases, we are looking forward to working with Orly and benefitting from her extensive experience in bringing new treatment options to heart failure patients," said Claudia Ulbrich, MD, CEO and Co-Founder of Cardior. "Her deep understanding of all stages of clinical development and the challenges of adopting new therapies into the current treatment landscape will be of significant importance to Cardior."

"The addition of Orly to the Board of Directors reflects Cardior's commitment to deliver a breakthrough for the current standard of care for heart diseases. The company has made significant progress by advancing CDR132L into Phase 2 clinical development and will profit from Orly's guidance as it further advances its lead candidate and broader pipeline," added Russell Greig, PhD, Chairman of Cardior's Board.

"RNA-based therapies stand apart in mechanism from traditional guideline directed medical therapy for heart failure, and I am a great supporter of identifying and evaluating novel treatment options in this area," added Dr. Vardeny. "Targeting non-coding RNAs as the master-regulators of indication-specific pathways to achieve disease-modifying effects is a very promising approach and I am looking forward to supporting the continued advancement of Cardior's exciting pipeline."

Orly Vardeny, PharmD, MS, is an Associate professor of Medicine at the University of Minnesota. Her research interests include maximizing the benefit of pharmacologic therapy in patients with heart failure and optimizing vaccination strategies in patients with cardiac disorders. She has led several multi-center, randomized clinical trials evaluating influenza vaccines in patients with high-risk cardiovascular disease. In addition, she serves as the US national lead investigator and a steering committee member for numerous clinical trials investigating novel therapies in patients with heart failure. Her clinical practice is in the outpatient management of patients with chronic heart failure. She is an Associate Editor for Circulation: Heart Failure and was a writing group member for the 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America Guidelines for the Management of Heart Failure.

***

About Cardior

Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. Cardior's therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. The company aspires to bring transformative therapeutics and diagnostics to patients and thereby make a lasting impact on the treatment of cardiac diseases worldwide.


These press releases may also interest you

4 fév 2023
Product photos are available: https://recalls-rappels.canada.ca/en/alert-recall/nutrifresh-brand-falooda-drinks-recalled-due-undeclared-milk-1 SummaryBrand(s): NutrifreshProduct: Falooda DrinksCompanies: Nutrifresh Foods Ltd.Issue: Food ? Allergen ?...

4 fév 2023
Today, Cohen Veterans Network (CVN) a not-for-profit philanthropic organization that serves post-9/11 veterans, active duty service members and their families through a nationwide system of mental health clinics, welcomed First Lady Jill Biden at its...

4 fév 2023
Egret Therapeutics, a clinical-stage biotechnology company focused on developing transformative therapies for neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND)...

4 fév 2023
The next Gentle Sleep Coach® online certification training program hosted by world-leading children's sleep coach, 'The Sleep Lady®' returns. Aligned with her gentle sleep philosophy, the program welcomes aspiring sleep coaches to participate in...

4 fév 2023
The number of patients seeking medical/dental care abroad, a practice called "medical...

4 fév 2023
A University of Maryland School of Medicine (UMSOM) physician-scientist will head a new federally-funded research program to develop and test a whole blood product, storable at room temperature, that can be used to transfuse wounded soldiers in the...



News published on 1 december 2022 at 05:05 and distributed by: